Mostrar el registro sencillo del ítem

dc.contributor.authorFrancisco, V.
dc.contributor.authorTovar Carro, Sulay
dc.contributor.authorConde, J.
dc.contributor.authorPino Mínguez, Jesús 
dc.contributor.authorMera Varela, Antonio 
dc.contributor.authorLago Paz, Francisca 
dc.contributor.authorGonzález-Gay, M. A.
dc.contributor.authorDiéguez González, Carlos
dc.contributor.authorGualillo ., Oreste 
dc.date.accessioned2022-04-26T07:42:07Z
dc.date.available2022-04-26T07:42:07Z
dc.date.issued2020
dc.identifier.issn2072-6643
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32268520es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16502
dc.description.abstractRheumatoid arthritis (RA) is a debilitating, chronic, inflammatory, autoimmune disease associated with cachexia. The substitutive therapy of gut hormone ghrelin has been pointed at as a potential countermeasure for the management of metabolic and inflammatory complications in RA. The recent discovery of liver-expressed antimicrobial peptide 2 (LEAP2) as an endogenous inverse agonist/antagonist of the ghrelin receptor makes feasible the development of a more rational pharmacological approach. This work aimed to assess the serum LEAP2 levels, in a cohort of RA patients, in comparison with healthy individuals and determine its correlation with inflammatory parameters. LEAP2 levels were determined by a commercial ELISA kit, plasma C-reactive protein (CRP) levels were evaluated using immunoturbidimetry, and serum levels of inflammatory mediators, namely IL-6, IL-8, IL-1beta, MIP1alpha, MCP1, and LCN2, were measured by XMap multiplex assay. LEAP2 serum levels were significantly increased in RA patients (n = 101) compared with control subjects (n = 26). Furthermore, the LEAP2 levels significantly correlated with CRP and inflammatory cytokines, but not with BMI. These data reveal LEAP2 as a new potential RA biomarker and indicated the pharmacological control of LEAP2 levels as a novel approach for the treatment of diseases with alterations on the ghrelin levels, such as rheumatoid cachexia.en
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshHumans*
dc.subject.meshCytokines*
dc.subject.meshAntimicrobial Cationic Peptides*
dc.subject.meshC-Reactive Protein*
dc.subject.meshBlood Proteins*
dc.subject.meshArthritis*
dc.titleLevels of the Novel Endogenous Antagonist of Ghrelin Receptor, Liver-Enriched Antimicrobial Peptide-2, in Patients with Rheumatoid Arthritisen
dc.typeJournal Articlees
dc.authorsophosFrancisco, V.;Tovar, S.;Conde, J.;Pino, J.;Mera, A.;Lago, F.;González-Gay, M. A.;Dieguez, C.;Gualillo, O.
dc.identifier.doi10.3390/nu12041006
dc.identifier.pmid32268520
dc.identifier.sophos39046
dc.issue.number4es
dc.journal.titleNutrientses
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Reumatoloxíaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Traumatoloxíaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)es
dc.page.initial1006es
dc.page.final1006es
dc.rights.accessRightsopenAccess
dc.subject.decsproteínas sanguíneas*
dc.subject.decscitocinas*
dc.subject.decshumanos*
dc.subject.decspéptidos catiónicos antimicrobianos*
dc.subject.decsproteína C reactiva*
dc.subject.decsartritis*
dc.subject.keywordCHUSes
dc.subject.keywordIDISes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number12es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional